Reboxetine - CAS 98769-81-4
Catalog number: B0084-283151
Category: Inhibitor
Please be kindly noted products are not for therapeutic use. We do not sell to patients.
Molecular Formula:
Molecular Weight:
orepinephrine reuptake
Reboxetine, also called as Vestra, 2-((2-ethoxyphenoxy)benzyl)morpholine methanesulfonate, exists as two enantiomers, (R,R)-(-)- and (S,S)-(+)-reboxetine. Ti is a selective norepinephrine reuptake inhibitor used in the treatment of clinical depression, panic disorder and ADD/ADHD which has been approved for treatment of major depression. In vitro: it inhibits noradrenaline reuptake in vitro to a similar extent to the tricyclic antidepressant desmethylimipramine and does not inhibit the activity of the following isozymes of cytochrome P450: CYP1A2, CYP2C9, CYP2C19, and CYP2E1; In vivo: Reboxetine does not affect dopamine or serotonin reuptake and it has low in vivo and in vitro affinity for adrenergic, cholinergic, histaminergic, dopaminergic and serotonergic receptors.Besides, it inhibits both CYP2D6 and CYP3A4 with low binding affinities, but has shown no effect on the in vivo clearance of drugs metabolized by these enzymes. Inhibits (±)-epibatidine-induced Ca(2+) influx in human (h) muscle embryonic (hα1β1γδ) and adult (hα1β1εδ) AChRs in a non-competitive manner , with potencies IC50= 3.86±0.49 and 1.92±0.48 μM, respectively.
≥ 95.0%
Off-White to Pale Beige Solid
(2R)-2-[(R)-(2-ethoxyphenoxy)-phenylmethyl]morpholine; 2-((2-ethoxyphenoxy)benzyl)morpholine methanesulfonate; reboxetine; reboxetine mesylate; Vestra; Reboxetine; Edronax (TN); AC1L2RJ0; Vestra; Reboxetine (INN); D08472; 98769-81-4; (2R)-2-[(R)-(2-ethoxyphenoxy)-phenylmethyl]morpholine; Morpholine, 2-((R)-(2-ethoxyphenoxy)phenylmethyl)-, (2R)-rel-; 71620-89-8; 98769-83-6; (R,R)-Reboxetine; eboxetine [INN:BAN]; SCHEMBL34533; CHEMBL383921; DTXSID1048257; HSDB 7701; ZINC3996032; AKOS015966368; AJ-47614; AN-34535; FT-0653731; FT-0699742; (2r)-2-[(R)-(2-Ethoxyphenoxy)(Phenyl)methyl]morpholine; (2R)-2-[(R)-(2-ethoxyphenoxy)-phenyl-methyl]morpholine; Morpholine,2-[(R)-(2-ethoxyphenoxy)phenylmethyl]-, (2R)-rel-; 41X
In water, 433 mg/L at 25ºC
A selective norepinephrine reuptake inhibitor used in the treatment of clinical depression, panic disorder and ADD/ADHD, has been approved for treatment of major depression;
Quality Standard:
In-house standard
Melting Point:
Canonical SMILES:
1.Risperidone-Induced Nocturnal Enuresis Successfully Treated With Reboxetine.
Mergui J1, Jaworowski S. Clin Neuropharmacol. 2016 Mar 17. [Epub ahead of print]
There are few reports in the literature and scarce research on the topic and the treatment of antipsychotic medication-induced urinary incontinence or nocturnal enuresis (NE) despite the significant frequency of these adverse effects.Treatment for antipsychotic medication-induced urinary incontinence has been reported in relation to clozapine with response to numerous pharmacological strategies such as ephedrine, oxybutynin, intranasal desmopressin, trihexyphenidyl, and amitriptyline.We report a case of NE induced by risperidone which has been successfully treated with reboxetine.To the best of our knowledge, this article is the first report of an atypical antipsychotic medication-induced NE treated with reboxetine.Reboxetine may be an effective treatment for risperidone-induced NE. Further research is required to confirm our finding and apply this treatment for NE caused by other neuroleptics.
2.Weight Loss Associated with Reboxetine Use in Adolescents.
Bozkurt H1, Şahin S1. J Child Adolesc Psychopharmacol. 2016 Feb;26(1):82-3. doi: 10.1089/cap.2015.0199. Epub 2016 Jan 27.
3.The norepinephrine reuptake inhibitor reboxetine is more potent in treating murine narcoleptic episodes than the serotonin reuptake inhibitor escitalopram.
Schmidt C1, Leibiger J2, Fendt M3. Behav Brain Res. 2016 Apr 23;308:205-210. doi: 10.1016/j.bbr.2016.04.033. [Epub ahead of print]
One of the major symptoms of narcolepsy is cataplexy, a sudden loss of muscle tone. Despite the advances in understanding the neuropathology of narcolepsy, cataplexy is still treated symptomatically with antidepressants. Here, we investigate in a murine narcolepsy model the hypothesis that the antidepressants specifically blocking norepinephrine reuptake are more potent in treating narcoleptic episodes than the antidepressants blocking of serotonin reuptake. Furthermore, we tested the effects of α1 receptor stimulation and blockade, respectively, on narcoleptic episodes. Orexin-deficient mice were treated with different doses of the norepinephrine reuptake inhibitor reboxetine, the serotonin reuptake inhibitor escitalopram, the α1 receptor agonist cirazoline or the α1 receptor antagonist prazosin. The effect of these treatments on narcoleptic episodes was tested. Additionally, potential treatment effects on locomotor activity in an open-field were tested.
4.Effects of escitalopram, R-citalopram, and reboxetine on serum levels of tumor necrosis factor-α, interleukin-10, and depression-like behavior in mice after lipopolysaccharide administration.
Dong C1, Zhang JC1, Yao W1, Ren Q1, Yang C1, Ma M1, Han M1, Saito R2, Hashimoto K3. Pharmacol Biochem Behav. 2016 May;144:7-12. doi: 10.1016/j.pbb.2016.02.005. Epub 2016 Feb 15.
Inflammation plays a role in the pathophysiology of depression. The purpose of this study is to examine whether the selective serotonin reuptake inhibitor (SSRI) escitalopram, its inactive enantiomer R-citalopram, and selective noradrenaline reuptake inhibitor (NRI) reboxetine, show anti-inflammatory and antidepressant effects in an inflammation-induced model of depression. Pretreatment with escitalopram (1, 3, or 10mg/kg, i.p.) markedly blocked an increase in the serum levels of pro-inflammatory cytokine, tumor necrosis factor-α (TNF-α), after a single administration of lipopolysaccharide (LPS; 0.5mg/kg). Furthermore, escitalopram (3 or 10mg/kg) significantly increased the serum levels of the anti-inflammatory cytokine interleukin-10 (IL-10) by a single administration of LPS. In contrast, pretreatment with R-citalopram (10mg/kg, i.p.) or reboxetine (10mg/kg, i.p.) did not affect the alterations in serum levels of TNF-α and IL-10 after LPS administration.
Molecular Weight Calculator Molarity Calculator Solution Dilution Calculator

Related Products

CAS 887650-05-7 Bafetinib

(CAS: 887650-05-7)

Bafetinib is a potent and selective dual Bcr-Abl/Lyn inhibitor, but it does not inhibit the phosphorylation of the T315I mutant and is less potent to PDGFR and ...

CAS 5534-95-2 Pentagastrin

(CAS: 5534-95-2)

Pentagastrin is a synthetic polypeptide used as a diagnostic aid for evaluation of gastric acid secretory function

CAS 138356-09-9 BD 1008 dihydrobromide

BD 1008 dihydrobromide
(CAS: 138356-09-9)

BD 1008 dihydrobromide is a potent and selective σ receptor antagonist displaying 4-fold selectivity for σ1 over σ2. BD-1008 attenuates the toxicity and stimula...

CAS 133920-70-4 FK 960

FK 960
(CAS: 133920-70-4)

FK 960 is a somatostatin receptor agonist and a 5-HT agonist activating both serotonin and somatostatin production as a cognitive enhancer. The phase II clinica...

CAS 134052-73-6 (S)-4-Carboxyphenylglycine

(CAS: 134052-73-6)

(S)-4-Carboxyphenylglycine has been found to be a competitive group I metabotropic glutamate receptor antagonist(S)-4-Carboxyphenylglycine has been found to be ...

(CAS: 1354037-26-5)

KH-CB19, a CLK1/CLK4 inhibitor, has been found to probably restrain the phosphorylation of serine- and arginine-rich (SR) proteins. IC50: 20 nM for CLK1.

CAS 73590-58-6 Omeprazole

(CAS: 73590-58-6)

Omeprazole is a proton pump inhibitor used in the treatment of dyspepsia. It binds to the proton pump hydrogen-potassium adenosine triphosphatase (H+/K+ ATPase)...

CAS 117704-25-3 Doramectin

(CAS: 117704-25-3)

Doramectin is a derivative of ivermectin, which is an anthelmintic. Doramectin is an antiparasitic antibiotic.

Chemical Structure

CAS 98769-81-4 Reboxetine

Quick Inquiry

Verification code

Featured Items